Lilly’s cardiovascular outcomes trial is the first to use an active comparator, finding noninferiority but not superiority of ...

In the SURPASS-CVOT trial, tirzepatide was similar to dulaglutide for prevention of cardiovascular death, heart attack and stroke at 4 years, researchers reported at the European Association for the ...

Continuing the upmanship battle in expanding the use of GLP-1 drugs beyond diabetes and obesity, Novo Nordisk has released ...

NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for ...

A pharmacist with 30 years experience says she would never take weight loss drugs as 'alarming' side effects are coming to ...

A new large-scale study came to the conclusion that weight-loss surgery gives people with type 2 diabetes and obesity a ...

The WHO has added GLP-1 agonists to its Essential Medicines List in 2025. Learn more about the impact of this decision.

SAN FRANCISCO and SUZHOU, China, Sept. 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical ...

The two observational studies have limitations, including use of older GLP-1s, but still point to the strengths of bariatric ...

Research indicates that external eating behavior is a key predictor of weight loss in type 2 diabetes patients receiving ...

GLP-1 agonists can lower blood sugar levels in people living with type 2 diabetes and can also be prescribed to support some ...